Format

Send to

Choose Destination
Cancer Lett. 2019 Oct 5;467:50-57. doi: 10.1016/j.canlet.2019.10.003. [Epub ahead of print]

ADAM proteases: Emerging role and targeting of the non-catalytic domains.

Author information

1
Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY, 10065, USA. Electronic address: sahan@mskcc.org.
2
Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY, 10065, USA.

Abstract

ADAM proteases are multi domain transmembrane metalloproteases that cleave a range of cell surface proteins and activate signaling pathways implicated in tumor progression, including those mediated by Notch, EFGR, and the Eph receptors. Consequently, they have emerged as key therapeutic targets in the efforts to inhibit tumor initiation and progression. To that end, two main approaches have been taken to develop ADAM antagonists: (i) small molecule inhibitors, and (ii) monoclonal antibodies. In this mini-review we describe the distinct features of ADAM proteases, particularly of ADAM10 and ADAM17, their domain organization, conformational rearrangements, regulation, as well as their emerging importance as therapeutic targets in cancer. Further, we highlight an anti-ADAM10 monoclonal antibody that we have recently developed, which has shown significant promise in inhibiting Notch signaling and deterring growth of solid tumors in pre-clinical settings.

KEYWORDS:

ADAM10; ADAM17; Integrins; Notch signaling; Therapeutic antibody

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center